Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 31 Neoplasms 8 Neoplasm Metastasis 8 Brain Neoplasms 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Glioma 4 Endometrial Neoplasms 4 Triple Negative Breast Neoplasms 3 Neoplasms by Site 3 Breast Diseases 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Meningioma 2 Liposarcoma 2 Head and Neck Neoplasms 2 Glioblastoma 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Kaposi 1 Sarcoma, Ewing 1 Sarcoma 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neoplasms, Squamous Cell 1 Neoplasm, Residual 1

Interventions

exemestane 2 Tamoxifen 2 Letrozole 2 Immunotherapy 2 Anastrozole 2 ribociclib 1 elacestrant 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abemaciclib 1 Taxes 1 Standard of Care 1 Radiosurgery 1 Psychiatric Rehabilitation 1 Practice Guidelines as Topic 1 Neoadjuvant Therapy 1 Methods 1 Mental Status and Dementia Tests 1 Leuprolide 1 Interviews as Topic 1 Goserelin 1 Genetic Testing 1 Genetic Counseling 1 Educational Status 1 Early Intervention, Educational 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms, Male × abemaciclib × 90 days × Clear all

NCT05501704 2026-04-30

ETHAN - ET for Male BC

Dana-Farber Cancer Institute

Phase 2 Recruiting

Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡